Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection

West, Howard; Hu, Xiaohan; Chirovsky, Diana; Walker, Mark S.; Wang, Yuexi; Kaushiva, Alpana; Tepsick, Jon; Samkari, Ayman

doi:10.2217/fon-2023-0024

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also reports the long-term survival outcomes for patients and includes additional analysis among patients who did not experience a recurrence by certain landmarks, to delve deeper into the experience of these patients. Findings from direct comparison of outcomes between patients who experienced a recurrence versus those who did not are reported in a separate manuscript and published elsewhere [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection

Hu,

Chirovsky,

Walker

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background Real-world data regarding patient characteristics, adjuvant treatment patterns, and long-term survival outcomes are needed to better understand unmet needs among patients with completely resected early-stage non-small cell lung cancer (NSCLC). Methods Electronic medical records from the U.S.-based ConcertAI Patient360™ database were analyzed in patients with stage IB-IIIA NSCLC who underwent complete resection prior to March 1, 2016. Patients were followed until death or July 1, 2021. This study evaluated adjuvant chemotherapy use, and overall survival (OS) and real-world disease-free survival (rwDFS) outcomes using the Kaplan–Meier method. The correlation between OS and rwDFS was assessed using the Kendall rank test. Among patients who did not recur 5 years following surgery, landmark analyses of OS and rwDFS were conducted to understand the subsequent survival impact of remaining disease-free for at least 5 years. Results Data from 441 patients with completely resected stage IB-IIIA NSCLC were included. About 35% of patients received adjuvant chemotherapy post-resection. Median OS and rwDFS from resection were 83.1 months and 42.4 months, respectively. The 5-year OS and rwDFS rates were 65.7% and 42.1%, respectively. OS and rwDFS were positively correlated (Kendall rank correlation coefficient = 0.67; p < 0.0001). Among patients without recurrence within 5 years after resection, the subsequent 5-year OS and rwDFS survival rates were 52.9% and 36.6%, respectively. Conclusions Use of adjuvant chemotherapy was low, and the overall 5-year OS rate remained low despite all patients having undergone complete resection. Patients who remained non-recurrent over time had favorable subsequent long-term survival.

show abstract

Section: Introductionmentioning

confidence: 99%